Any current/future new fundraising through debt or equity?

The transcript provided does not explicitly mention any current or planned fundraising activities through debt or equity. The company is undertaking a significant capex plan of INR 1,100 crores between FY '24 and FY '28, split evenly between Essentials and Specialties. The management mentioned leveraging an "un-leveraged balance sheet" indicating capacity for investment but did not specify plans to raise new funds. They focused on ongoing projects and operational expansions funded within existing resources. No direct references to raising capital through debt or equity financing were made duri

Any current/future capex/capital investment/strategic investment?

Laxmi Organic has planned a total capex of INR 1,100 crores from FY '24 to FY '28, evenly split between Essentials (INR 550 crores) and Specialties (INR 550 crores). A new world-scale n-butyl acetate plant (70 KT capacity) is being set up at Dahej with a capex of about INR 90 crores, serving as a 100% import substitute product. A world-scale ethyl acetate line is planned at Lote, Maharashtra, with a capex of INR 90 crores, leveraging government mega status incentives. The Lote facility has additional land available for up to INR 400 crores more capex, mainly for expansion in fluorine verticals

Future growth expectations in sales/revenue/volumes?

Laxmi Organic aims to double revenues from FY '24 to FY '28, targeting INR 200 crore peak revenue by FY '27 in Specialty products. Volume growth in Essential chemicals strong with 20% year-on-year increase and 16% sequential growth. Expected continued double-digit top-line and volume growth in Q3 FY '25, with predictability and confidence building internally and with customers. New capacity expansions such as the 70 KT/annum n-butyl acetate plant at Dahej to drive import substitution and market expansion. Specialty business to contribute 10-15% of peak revenues by Q4 FY '25, increasing to 40-6

Future growth expectations in earnings/operating earnings/profits/EPS?

Laxmi Organic delivered double-digit top-line, volume, and bottom-line growth in Q2 FY '25 and H1 FY '25 despite market challenges, signaling strong operational momentum. The company aims to sustain year-on-year growth into Q3 FY '25 as per management's guidance. EBITDA for Q2 (~INR 75 crores) is targeted as a sustainable baseline, with ambitions to increase via pricing improvements or additional capacity expansions. Their Specialty chemicals division targets robust EBITDA margins of 20%-25%, independent of market cycles, supporting steady profit growth. Capex of INR 1,100 crores (equally spli

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders details. However, the company discussed operational progress and commercial production plans, especially: - Fluoro intermediate site focusing on scaling plant and starting revenue generation in the second half of FY '25. - Dahej project on track to receive pending regulatory approvals and progressing on time and budget. Management expressed confidence in continued year-on-year growth in Q3 FY '25, implying steady order inflow. Customer approvals have increased for Fluorochemicals products (16 ou

IN US

Sale is live|00:00:00left today

Laxmi Organic Industries LtdQ3 FY24Chemicals & Petrochemicals

Laxmi Organic Industries Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹163P/E: 53.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Laxmi Organic aims to double revenues from FY '24 to FY '28, targeting INR 200 crore peak revenue by FY '27 in Specialty products.
→Volume growth in Essential chemicals strong with 20% year-on-year increase and 16% sequential growth.
→Expected continued double-digit top-line and volume growth in Q3 FY '25, with predictability and confidence building internally and with customers.
→New capacity expansions such as the 70 KT/annum n-butyl acetate plant at Dahej to drive import substitution and market expansion.
→Specialty business to contribute 10-15% of peak revenues by Q4 FY '25, increasing to 40-60% in the next financial year.
→Focus on diversifying industry applications (pharma, agro, pigments, personal care) to ensure stability and growth.
→Operational excellence and cost improvement initiatives support sustainable EBITDA growth around INR 75 crores per quarter.

Margin guidance

Category 3

→Laxmi Organic delivered double-digit top-line, volume, and bottom-line growth in Q2 FY '25 and H1 FY '25 despite market challenges, signaling strong operational momentum.
→The company aims to sustain year-on-year growth into Q3 FY '25 as per management's guidance.
→EBITDA for Q2 (~INR 75 crores) is targeted as a sustainable baseline, with ambitions to increase via pricing improvements or additional capacity expansions.
→Their Specialty chemicals division targets robust EBITDA margins of 20%-25%, independent of market cycles, supporting steady profit growth.
→Capex of INR 1,100 crores (equally split between Essentials and Specialties) is expected to double revenues and improve ROCE to 20% by FY '28.
→New product launches, capacity expansions (e.g., ethyl acetate, butyl acetate), and expansion into new industries are key drivers.
→The Fluoro-intermediate plant scaling and upcoming Dahej approvals will contribute future revenue.
→Diversification across geographies and industries adds to earnings visibility and growth stability.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript provided does not explicitly mention any current or planned fundraising activities through debt or equity.
→The company is undertaking a significant capex plan of INR 1,100 crores between FY '24 and FY '28, split evenly between Essentials and Specialties.
→The management mentioned leveraging an "un-leveraged balance sheet" indicating capacity for investment but did not specify plans to raise new funds.
→They focused on ongoing projects and operational expansions funded within existing resources.
→No direct references to raising capital through debt or equity financing were made during the Q2 FY '25 earnings call.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders details.
→However, the company discussed operational progress and commercial production plans, especially:
→ - Fluoro intermediate site focusing on scaling plant and starting revenue generation in the second half of FY '25.
→ - Dahej project on track to receive pending regulatory approvals and progressing on time and budget.
→Management expressed confidence in continued year-on-year growth in Q3 FY '25, implying steady order inflow.
→Customer approvals have increased for Fluorochemicals products (16 out of 20 customers approved), indicating potential forthcoming orders.
→The specialty vertical sees expanding products and customers, supporting a positive demand outlook.
→No specific numeric or timeline details on the order book or pending orders provided in this transcript.

Capex plans

Yes

→Laxmi Organic has planned a total capex of INR 1,100 crores from FY '24 to FY '28, evenly split between Essentials (INR 550 crores) and Specialties (INR 550 crores).
→A new world-scale n-butyl acetate plant (70 KT capacity) is being set up at Dahej with a capex of about INR 90 crores, serving as a 100% import substitute product.
→A world-scale ethyl acetate line is planned at Lote, Maharashtra, with a capex of INR 90 crores, leveraging government mega status incentives.
→The Lote facility has additional land available for up to INR 400 crores more capex, mainly for expansion in fluorine verticals and fluoro-intermediates.
→Specialty vertical investments focus on diketene derivatives, fluorination, and broadening product baskets, targeting 10%-15% of peak revenues by FY '25 and 40%-60% by FY '26, reaching full peak in FY '27.

How does Laxmi Organic Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Laxmi Organic Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Laxmi Organic Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio